A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Eli Lilly and Co. plans to set up a $31 million digital health innovation hub in Singapore, expanding its research and ...

The stock of Eli Lilly and Company LLY has declined 10.6% in a month ... Lilly’s revenue growth is being driven by higher ...

"Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company that develops diabetes, oncology, immunology and ...

Tumors outside the central nervous system (CNS) did respond but the failure to shrink brain tumors took away TNG908’s raison d'etre. Tango has another MTA-cooperative PRMT5 inhibitor, TNG462, for ...

Discover the top 10 biggest companies in the world in 2024, featuring industry giants leading the global economy.

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Here's why Eli Lilly is a no-brainer stock to buy on the dip ... Sales for breast cancer drug Verzenio jumped 32% year over ...

Threats: Intense competition and patent expirations leading to generic competition.

Joe Fletcher; Senior Vice President of Investor Relations; Eli Lilly and Co David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice ...

While the performance of Zepbound and Mounjaro was disappointing, other areas of Eli Lilly's portfolio saw growth. The company's breast cancer drug Verzenio posted a 32% increase in sales, reaching $1 ...